Gynecologic and Obstetric Investigation
Original Paper
Perinatal Outcome in HIV-Infected Pregnant WomenSemprini A.E.a · Ravizza M.a · Bucceri A.b · Vucetich A.a · Pardi G.aaDepartment of Obstetrics and Gynecology, University of Milano Medical School, Ospedale S. Paolo; bUSSL 75/1, Milano, Italy
|
|
Log in to MyKarger to check if you already have access to this content.
KAB
Buy a Karger Article Bundle (KAB) and profit from a discount!
If you would like to redeem your KAB credit, please log in.
Save over 20% compared to the individual article price.
Article / Publication Details
Received: September 13, 1989
Accepted: December 22, 1989
Published online: March 02, 2010
Issue release date: 1990
Number of Print Pages: 4
Number of Figures: 0
Number of Tables: 0
ISSN: 0378-7346 (Print)
eISSN: 1423-002X (Online)
For additional information: https://www.karger.com/GOI
Abstract
We have observed 74 HIV-seropositive and 48 HIV-seronegative drug-addicted women and 22 HIV seropositive nondrug-addicted pregnant women during pregnancy and we report their perinatal outcome. 8 out of 96 HIV-seropositive patients had hematological signs of immunodeficiency and 2 of these patients were symptomatic belonging to CDC class III. WE recorded 2 early and 3 late spontaneous abortions, no intrauterine fetal death and 3 neonatal deaths. Seropositive patients had 3 malformed babies, seronegative patients had 1. All these women had a high incidence of premature delivery and intrauterine fetal growth retardation: seropositive patients had a higher incidence of fetuses small for gestational age and a lower incidence of preterm delivery compared to seronegative patients, but the difference was not statistically significant. The incidence of malformation was comparable to the general population: 3 malformed babies were born to HIV-positive drug-addicted mothers, and 1 to a seronegative drug-addicted mother. These findings do not support the hypothesis of a direct detrimental effect of HIV on perinatal outcome. Consequences of fetal exposure to maternal HIV infection involve mostly postnatal life and development of acquired immunodeficiency.
© 1990 S. Karger AG, Basel
Related Articles:
Article / Publication Details
Received: September 13, 1989
Accepted: December 22, 1989
Published online: March 02, 2010
Issue release date: 1990
Number of Print Pages: 4
Number of Figures: 0
Number of Tables: 0
ISSN: 0378-7346 (Print)
eISSN: 1423-002X (Online)
For additional information: https://www.karger.com/GOI
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.

Get Permission